Novartis Gleevec Gains Five Orphan Cancer Indications
This article was originally published in The Pink Sheet Daily
Executive Summary
Simultaneous approvals add a solid tumor cancer and four blood disorders to the targeted oncologic’s labeling, for a total of seven indications in five years.
You may also be interested in...
Gleevec Buoyed By GIST Trial Results; Novartis Will Seek Adjuvant Indication
NCI-sponsored study halted after imatinib meets primary endpoint, rate of recurrence-free survival, in Kit-positive GIST patients.
Gleevec Buoyed By GIST Trial Results; Novartis Will Seek Adjuvant Indication
NCI-sponsored study halted after imatinib meets primary endpoint, rate of recurrence-free survival, in Kit-positive GIST patients.
Novartis Oncology President David Epstein: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
Novartis’ oncology chief discusses in-licensing candidates, as well as how biologics fit into the firm’s oncology pipeline.